JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fleckenstein, A. E.
Right arrow Articles by Hanson, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fleckenstein, A. E.
Right arrow Articles by Hanson, G. R.

Vol. 282, Issue 2, 834-838, 1997

Rapid and Reversible Effects of Methamphetamine on Dopamine Transporters1

Annette E. Fleckenstein, Ryan R. Metzger, Diana G. Wilkins, James W. Gibb and Glen R. Hanson

Department of Pharmacology and Toxicology (A.E.F., R.R.M., J.W.G., G.R.H.) and Center for Human Toxicology (D.G.W.), University of Utah, Salt Lake City, Utah

Reactive oxygen species decrease dopamine transporter (DAT) function in vitro. Because of this, and the finding that METH administration causes oxygen radical formation in vivo, the effects of METH administration on DAT activity in rat striatum were investigated. A single METH injection caused a dose-dependent (0-15 mg/kg) decrease in [3H]dopamine uptake into striatal synaptosomes prepared 1 h after METH administration; an effect attributable to a decreased Vmax of [3H]dopamine uptake. Similarly, multiple high-dose administrations of METH (10 mg/kg/dose; four doses at 2-h intervals) decreased DAT function. The decreases in DAT activity after either single or multiple METH administrations were reversed 24 h after treatment. [3H]5HT transport into striatal synaptosomes was also affected by METH treatment. Taken together, these data suggest that METH decreases DAT activity, perhaps through a reactive oxygen species-mediated mechanism. These findings may have important implications regarding the role of oxidative events in the physiological regulation of monoaminergic systems.

Copyright © by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Neurosci.Home page
M. Niwa, A. Nitta, H. Mizoguchi, Y. Ito, Y. Noda, T. Nagai, and T. Nabeshima
A Novel Molecule "Shati" Is Involved in Methamphetamine-Induced Hyperlocomotion, Sensitization, and Conditioned Place Preference
J. Neurosci., July 11, 2007; 27(28): 7604 - 7615.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Z. Xie and G. M. Miller
Trace Amine-Associated Receptor 1 Is a Modulator of the Dopamine Transporter
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 128 - 136.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. S. Rau, E. Birdsall, T. J. Volz, J. A. Riordan, A. J. Baucum II, B. P. Adair, R. Bitter, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein
Methamphetamine Administration Reduces Hippocampal Vesicular Monoamine Transporter-2 Uptake
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 676 - 682.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. A. Cervinski, J. D. Foster, and R. A. Vaughan
Psychoactive Substrates Stimulate Dopamine Transporter Phosphorylation and Down-regulation by Cocaine-sensitive and Protein Kinase C-dependent Mechanisms
J. Biol. Chem., December 9, 2005; 280(49): 40442 - 40449.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Escubedo, C. Chipana, M. Perez-Sanchez, J. Camarasa, and D. Pubill
Methyllycaconitine Prevents Methamphetamine-Induced Effects in Mouse Striatum: Involvement of {alpha}7 Nicotinic Receptors
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 658 - 667.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. A. Vaughan
Phosphorylation and Regulation of Psychostimulant-Sensitive Neurotransmitter Transporters
J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 1 - 7.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. L. Johnson-Davis, J. G. Truong, A. E. Fleckenstein, and D. G. Wilkins
Alterations in Vesicular Dopamine Uptake Contribute to Tolerance to the Neurotoxic Effects of Methamphetamine
J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 578 - 586.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
A. J. Baucum II, K. S. Rau, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein
Methamphetamine Increases Dopamine Transporter Higher Molecular Weight Complex Formation via a Dopamine- and Hyperthermia-Associated Mechanism
J. Neurosci., March 31, 2004; 24(13): 3436 - 3443.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
A. Nakajima, K. Yamada, T. Nagai, T. Uchiyama, Y. Miyamoto, T. Mamiya, J. He, A. Nitta, M. Mizuno, M. H. Tran, et al.
Role of Tumor Necrosis Factor-{alpha} in Methamphetamine-Induced Drug Dependence and Neurotoxicity
J. Neurosci., March 3, 2004; 24(9): 2212 - 2225.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. S. Middleton, W. A. Cass, and L. P. Dwoskin
Nicotinic Receptor Modulation of Dopamine Transporter Function in Rat Striatum and Medial Prefrontal Cortex
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 367 - 377.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. L. CADET, S. JAYANTHI, and X. DENG
Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis
FASEB J, October 1, 2003; 17(13): 1775 - 1788.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Sorkina, S. Doolen, E. Galperin, N. R. Zahniser, and A. Sorkin
Oligomerization of Dopamine Transporters Visualized in Living Cells by Fluorescence Resonance Energy Transfer Microscopy
J. Biol. Chem., July 18, 2003; 278(30): 28274 - 28283.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
V. Sandoval, E. L. Riddle, G. R. Hanson, and A. E. Fleckenstein
Methylphenidate Redistributes Vesicular Monoamine Transporter-2: Role of Dopamine Receptors
J. Neurosci., October 1, 2002; 22(19): 8705 - 8710.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. M. Brown, E. L. Riddle, V. Sandoval, R. K. Weston, J. E. Hanson, M. J. Crosby, Y. V. Ugarte, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein
A Single Methamphetamine Administration Rapidly Decreases Vesicular Dopamine Uptake
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 497 - 501.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
S. U. Park, J. V. Ferrer, J. A. Javitch, and D. M. Kuhn
Peroxynitrite Inactivates the Human Dopamine Transporter by Modification of Cysteine 342: Potential Mechanism of Neurotoxicity in Dopamine Neurons
J. Neurosci., June 1, 2002; 22(11): 4399 - 4405.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. P. Hansen, E. L. Riddle, V. Sandoval, J. M. Brown, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein
Methylenedioxymethamphetamine Decreases Plasmalemmal and Vesicular Dopamine Transport: Mechanisms and Implications for Neurotoxicity
J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1093 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. M. Brown, G. R. Hanson, and A. E. Fleckenstein
Cocaine-Induced Increases in Vesicular Dopamine Uptake: Role of Dopamine Receptors
J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1150 - 1153.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
V. Sandoval, E. L. Riddle, Y. V. Ugarte, G. R. Hanson, and A. E. Fleckenstein
Methamphetamine-Induced Rapid and Reversible Changes in Dopamine Transporter Function: An In Vitro Model
J. Neurosci., February 15, 2001; 21(4): 1413 - 1419.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. R. Metzger, H. M. Haughey, D. G. Wilkins, J. W. Gibb, G. R. Hanson, and A. E. Fleckenstein
Methamphetamine-Induced Rapid Decrease in Dopamine Transporter Function: Role of Dopamine and Hyperthermia
J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1077 - 1085.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Kim, R. Westphalen, B. Callahan, G. Hatzidimitriou, J. Yuan, and G. A. Ricaurte
Toward Development of an In Vitro Model of Methamphetamine-Induced Dopamine Nerve Terminal Toxicity
J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 625 - 633.
[Abstract] [Full Text]

Home page
 J. Neurosci.Home page
X. Deng, B. Ladenheim, L.-I Tsao, and J. L. Cadet
Null Mutation of c-fos Causes Exacerbation of Methamphetamine-Induced Neurotoxicity
J. Neurosci., November 15, 1999; 19(22): 10107 - 10115.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. K. Yamamoto and W. Zhu
The Effects of Methamphetamine on the Production of Free Radicals and Oxidative Stress
J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 107 - 114.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.